SillaJen, Inc.
KOSDAQ 215600.KQ
SillaJen, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 82.94
SillaJen, Inc. Price to Sales Ratio (P/S) is 82.94 on January 14, 2025, a -55.54% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
-
SillaJen, Inc. 52-week high Price to Sales Ratio (P/S) is 190.50 on March 22, 2024, which is 129.69% above the current Price to Sales Ratio (P/S).
-
SillaJen, Inc. 52-week low Price to Sales Ratio (P/S) is 75.22 on December 23, 2024, which is -9.30% below the current Price to Sales Ratio (P/S).
-
SillaJen, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 123.77.
Key data
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
Market news
Loading...
KOSDAQ: 215600.KQ
| CEO | Mr. Jaekyung Kim |
| IPO Date | Dec. 6, 2016 |
| Location | South Korea |
| Headquarters | O2 Tower |
| Employees | 37 |
| Sector | Health Care |
| Industries | |
Description
SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email